Illumina MiSeq i100 System

Summary (Newest Update)

Background The Food and Drug Administration (FDA), Irvine Medical Products Laboratory (IRVLMP), is responsible for performing microbiological testing on medical products to ensure compliance with USP and other regulatory requirements. The goal of this contract is to acquire one (1) Illumina MiSeq i100 Whole Genome Sequencing System, which is the only system capable of meeting the Government’s minimum requirements for compatibility with existing validated laboratory workflows, consumables, sequencing methods, software environments, and operational procedures. The procurement includes associated components, software, delivery, installation, training, and manufacturer warranty support. Work Details The contract requires the provision of one (1) Illumina MiSeq i100 Whole Genome Sequencing System with the following salient characteristics: - Uses sequencing-by-synthesis next-generation sequencing technology. - Supports single-read and paired-end libraries. - Output range up to 25 Gigabases. - Up to 50 million paired-end reads per run. - Maximum read length of at least 2 x 300 base pairs. - Quality score greater than or equal to 85% of bases higher than Q30 when using a 2 x 300bp flow cell type. - RFID or equivalent technology for tracking consumables. - Kit reagents should require room-temperature storage. - Data collection software included for instrument control and onboard sequence alignment. - Monitor and computer included to run instrument control software. - Benchtop model with footprint no larger than 16 inches x 18 inches x 26 inches (WxDxH). - One-year manufacturer warranty for equipment parts and operational services. - All equipment must be new, not used or refurbished. Place of Performance Irvine, CA